Fig. 7

YAP combined GLUT1 may serve as a valuable prognostic and/or diagnostic biomarker in liver cancer. A and B GLUT1 IHC staining in liver cancer patient samples. Images of cells were used to evaluate GLUT1 expression between the normal and the tumor. C GLUT1 IHC staining in liver cancer patient samples. Representative GLUT1-stained images of TNM stage I, II, III and IV liver cancer tumor tissues were quantified. D Kaplan–Meier approach visualized the relationship between GLUT1 expression and OS in liver cancer patients (n = 53, P < 0.001) E Time-dependent ROC curves analyzing the potential value of expression levels of GLUT1. F Kaplan–Meier curve for the disease free survival and overall survival have been illustrated for the subgroups YAP high/GLUT1 low, YAP high/GLUT1 high, YAP low/GLUT1 low and YAP low/GLUT1 high. G Nomogram for predicting the stage according to the expression levels of GLUT1 and YAP. Instruction: Each characteristic was located on the corresponding variable axis, and a vertical line was drawn upwards to the points axis to determine the specific point value. This process was repeated and the total points value was tallied and located on the linear pretector axis. A vertical line was drawn down to the rank to obtain the probability of later stage